An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer

N/ACompletedNCT01194050

Hoffmann-La Roche289 enrolled

Overview

This observational study will investigate the tolerability and efficacy of Tarceva (erlotinib) in daily clinical practice under routine conditions in patients with locally advanced or metastatic non small cell lung cancer. Data will be collected for approximately 12 months.

Study Type

OBSERVATIONAL

Enrollment

289

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients with locally advanced or metastatic non-small cell lung cancer (stage IIIb or IV) with stable disease after 4 cycles of standard platinum-based first-line chemotherapy Exclusion Criteria: * Not willing or not able to sign written informed consent form

Locations (1)

Unnamed facility

Villingen-Schwenningen, Germany

Outcomes

Primary Outcomes

Overall survival at 1 year

Time frame: 12 months

Secondary Outcomes

Tolerability of Tarceva in daily clinical practice under routine conditions

Time frame: 12 months

Efficacy of Tarceva in daily clinical practice under routine conditions

Time frame: 12 months

Reproducibility of the results of the controlled SATURN study

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.